文献速递脑血管病头痛与眩晕

特发性颅内高压的微小RNA生物标志物初探

Identifying MicroRNA Biomarkers in Idiopathic Intracranial Hypertension: A Pilot Study.
PubMed 文献 · Neurology · 2026-06-17

该先导研究基于IIH-Weight试验的血清与脑脊液样本,检测40种候选微小RNA。结果发现活动期IIH患者血清hsa-miR-16-5p显著降低,对活动期IIH的诊断曲线下面积为0.951,并可区分缓解期、肥胖与偏头痛对照,且与颅内压和视乳头水肿相关。

要点

  • 血清hsa-miR-16-5p在活动期IIH中显著降低,诊断AUC达0.951。
  • hsa-miR-16-5p可区分活动期IIH与缓解期、肥胖及偏头痛。
  • 血清与脑脊液hsa-miR-16-5p均与颅内压和视乳头水肿相关。

核心结论

  • 血清hsa-miR-16-5p是与活动期IIH相关的候选生物标志物,可区分活动期与缓解期、偏头痛及肥胖。
  • 该标志物与疾病活动的临床及代谢指标相关,需在更大样本中验证其作为微创诊断与监测工具的潜力。

研究设计与样本

  • 基于IIH-Weight随机对照试验(比较减重手术与社区体重管理对降低颅内压的效果,2014-2017年招募)的基线与12个月血清和脑脊液样本分析。
  • 纳入活动期IIH成年女性,排除无视乳头水肿者;以肥胖和偏头痛参与者为对照;检测40种候选微小RNA。
  • 采用Student t检验和单因素方差分析及Tukey多重比较,并用线性回归评估差异表达微小RNA与临床活动度及代谢谱的关系。

主要发现

  • 40种血清微小RNA中有5种在活动期IIH(n=9,100%女性,平均30.25±4.75岁)较缓解期显著低表达。
  • 血清hsa-miR-16-5p对活动期IIH诊断性能最高,AUC为0.951。
  • 活动期IIH血清hsa-miR-16-5p(p<0.0001;CI -7.286至-2.503)和hsa-miR-7-5p(p=0.0032;CI -7.240至-1.372)显著低于肥胖对照(n=9,100%女性,平均38.22±7.99岁)。
  • 活动期IIH血清hsa-miR-7a-5p显著高于偏头痛对照(n=12,100%女性,平均44.67±8.88岁);仅hsa-miR-16-5p能同时区分偏头痛和肥胖对照。
  • 脑脊液hsa-miR-16-5p亦可区分活动期IIH与缓解期(p=0.0354;CI -3.062至-0.1282),且血清与脑脊液hsa-miR-16-5p均与颅内压(血清p<0.0001;CI -0.1660至-0.0732;脑脊液p=0.046;CI 0.0018-0.1841)和视乳头水肿(血清p=0.0236;CI -0.01548至-0.0001;脑脊液p=0.0241;CI 0.002-0.033)显著相关。

关键数值与推荐

  • 活动期IIH血清hsa-miR-16-5p诊断AUC为0.951。
  • 活动期IIH与肥胖对照比较:hsa-miR-16-5p p<0.0001(CI -7.286至-2.503),hsa-miR-7-5p p=0.0032(CI -7.240至-1.372)。
  • 脑脊液hsa-miR-16-5p区分活动期与缓解期:p=0.0354(CI -3.062至-0.1282)。
  • hsa-miR-16-5p与颅内压相关:血清p<0.0001(CI -0.1660至-0.0732),脑脊液p=0.046(CI 0.0018-0.1841)。
  • hsa-miR-16-5p与视乳头水肿相关:血清p=0.0236(CI -0.01548至-0.0001),脑脊液p=0.0241(CI 0.002-0.033)。

临床怎么用

  • 在成年女性IIH中,血清hsa-miR-16-5p有潜力作为区分活动期与缓解期及对照的微创标志物。
  • 该标志物与颅内压和视乳头水肿相关,未来或可用于疾病活动度监测,但尚需更大样本验证。
  • 目前证据等级为Class III,暂不能替代腰椎穿刺等现有诊断与监测手段。

局限性

  • 本研究为先导研究,活动期IIH样本量仅9例,统计效能有限。
  • 仅纳入成年女性,结果不能外推至男性或儿童IIH患者。
  • 证据等级为Class III,需在更大规模研究中验证后方可用于临床。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Idiopathic intracranial hypertension (IIH) is characterized by raised intracranial pressure (ICP). It predominantly affects women with obesity and can cause disabling headaches and permanent visual loss. IIH is misdiagnosed in up to 40% of cases. Diagnosis and monitoring often rely on frequent invasive lumbar puncture. This pilot study aimed to identify serum microRNA (miRNA) markers associated with a diagnosis of IIH and disease activity and to assess their relevance in the CNS through identification in CSF. METHODS: Serum and CSF samples from participants in the IIH-Weight Trial (a randomized controlled trial comparing the effectiveness of bariatric surgery with that of a community weight management intervention in lowering ICP, recruited 2014-2017) were analyzed at baseline (active disease) and 12 months (participants in remission with no papilledema). Eligible participants were adult women with active IIH (those without papilledema were excluded). Disease activity was assessed by quantifying the degree of papilledema using Spectralis spectral-domain optical coherence tomography. A panel of 40 candidate miRNAs was assessed. Comparator groups included participants with obesity or migraine. Analyses used Student t tests and one-way ANOVA followed by Tukey multiple comparisons test. Differentially expressed miRNAs were evaluated in relation to clinical disease activity and metabolic profiles, using linear regression analysis. RESULTS: Five of 40 serum miRNAs showed significantly lower expression in active IIH (n = 9; 100% female, mean 30.25 ± 4.75 years) compared with IIH in remission. Serum hsa-miR-16-5p had the highest diagnostic performance for active IIH (area under the curve 0.951). Serum hsa-miR-16-5p (p < 0.0001; CI -7.286 to -2.503) and hsa-miR-7-5p (p = 0.0032; CI -7.240 to -1.372) were significantly lower in active IIH compared with obesity controls (n = 9; 100% female, mean 38.22 ± 7.99 years). Serum hsa-miR-7a-5p were significantly higher in active IIH compared with migraine (n = 12; 100% female, mean 44.67 ± 8.88 years). Only hsa-miR-16-5p differentiated active IIH from both participants with migraine and obesity. hsa-miR-16-5p also differentiated active IIH from IIH remission in CSF (p = 0.0354; CI -3.062 to -0.1282). Serum and CSF hsa-miR-16-5p correlated significantly with ICP (serum p < 0.0001; CI -0.1660 to -0.0732; CSF p = 0.046; CI 0.0018-0.1841), papilledema (serum p = 0.0236; CI -0.01548 to -0.0001; CSF p = 0.0241; CI 0.002-0.033). hsa-miR-16-5p was associated with metabolites involved in fatty acid metabolism and lipid biosynthesis. DISCUSSION: Serum hsa-miR-16-5p emerged as a candidate biomarker associated with active IIH. It differentiated active disease from remission, migraine, and obesity. It correlated with clinical and metabolic markers of disease activity. These findings warrant validation in larger studies to assess its potential as a minimally invasive biomarker for IIH diagnosis and monitoring. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that serum microRNA markers may potentially distinguish active idiopathic intracranial hypertension from remission and controls in adult women.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Hill LJ, Begum G, Thomas CN, et al. Identifying MicroRNA Biomarkers in Idiopathic Intracranial Hypertension: A Pilot Study. Neurology. 2026. PMID: 42308437. doi:10.1212/WNL.0000000000218162

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。